Shelia M. Violette net worth and biography

Shelia Violette Biography and Net Worth

Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a sci of Q32 Bio

Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a scientific leader in the field of inflammation, autoimmunity and fibrosis. In her more than 20 years of industry experience advancing programs from early research to clinical development, Shelia has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 90 manuscripts and patents. Prior to co-founding Q32 Bio, she was an Entrepreneur in Residence at Atlas Venture. Prior to her role at Atlas, Shelia served in leadership roles in the Immunology Research group at Biogen, joining Stromedix as Vice President of Research and returning to Biogen as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including Repligen and Ariad. She received her Ph.D. in Pharmacology from Yale University.

What is Shelia M. Violette's net worth?: The estimated net worth of Shelia M. Violette is at least $1.03 million as of February 25th, 2026. Dr. Violette owns 55,569 shares of Q32 Bio stock worth more than $1,025,804 as of July 15th. This net worth evaluation does not reflect any other investments that Dr. Violette may own. Learn More about Shelia M. Violette's net worth.
How do I contact Shelia M. Violette?: The corporate mailing address for Dr. Violette and other Q32 Bio executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Q32 Bio can also be reached via phone at 781-301-7277 and via email at [email protected]. Learn More on Shelia M. Violette's contact information.
Has Shelia M. Violette been buying or selling shares of Q32 Bio?: Shelia M. Violette has not been actively trading shares of Q32 Bio in the last ninety days. Most recently, Shelia M. Violette sold 2,815 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a transaction totalling $12,695.65. Following the completion of the sale, the insider now directly owns 55,569 shares of the company's stock, valued at $250,616.19. Learn More on Shelia M. Violette's trading history.
Who are Q32 Bio's active insiders?: Q32 Bio's insider roster includes Lee Kalowski (PRESIDENT & CHIEF FINANCIAL OFFICER), Jodie Morrison (CEO), Shelia Violette (Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a sci), and Diyong Xu (Director). Learn More on Q32 Bio's active insiders.
Are insiders buying or selling shares of Q32 Bio?: In the last year, Q32 Bio insiders bought shares 2 times. They purchased a total of 3,750,000 shares worth more than $30,000,000.00. In the last year, insiders at the sold shares 8 times. They sold a total of 66,008 shares worth more than $216,507.14. The most recent insider tranaction occured on May, 28th when Director Diyong Xu bought 1,875,000 shares worth more than $15,000,000.00. Insiders at Q32 Bio own 34.5% of the company. Learn More about insider trades at Q32 Bio.
Information on this page was last updated on 5/28/2026.

Shelia M. Violette Insider Trading History at Q32 Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/25/2026	Sell	2,815	$4.51	$12,695.65	55,569
8/26/2025	Sell	2,990	$1.80	$5,382.00	58,384

Shelia M. Violette Buying and Selling Activity at Q32 Bio

Q32 Bio Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Today's Range

Now: $17.51

$17.11

$18.26

50 Day Range

MA: $10.81

$5.18

$21.38

2 Week Range

Now: $17.51

$1.57

$23.57

Volume

2,744,181 shs

Average Volume

749,677 shs

Market Capitalization

$296.99 million

P/E Ratio

6.58

Dividend Yield

N/A

Beta

0.24